Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development

The Alzheimer disease treatment landscape is rapidly changing, with several new FDA-approved antibody therapies that target amyloid plaque and aim to slow disease progression. While the controversial approval of aducanumab faced challenges, newer drugs like lecanemab and donanemab have shown more promising results in clinical trials, demonstrating cognitive benefits. Additionally, the pipeline includes novel therapies targeting tau protein and other mechanisms. Advancements in biomarker development, including plasma and imaging tests, are also enabling earlier diagnosis and the potential for preventive treatments before the onset of clinical symptoms.

Experts Include:
Pamela Spicer, neuroscience expert and therapy area Director, Citeline
Martin Tolar, MD, PhD, founder, president, CEO, Alzheon
Sharon Cohen, MD, FRCPC, medical director, site principal investigator, Toronto Memory Program